0NN Stock Chart & Stats
€0.08
>-€0.01(-1.23%)
At close: 4:00 PM EDT
€0.08
>-€0.01(-1.23%)
Day’s Range― - ―
52-Week Range€0.06 - €0.19
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€9.21M
Enterprise Value€25.16
Total Cash (Recent Filing)€200.42K
Total Debt (Recent Filing)€169.56K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding134,383,850
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)9.08
Price to Sales (P/S)1.01
P/FCF Ratio-17.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Gross MarginGross margins above 50% in 2024–TTM show that Avicanna’s products retain meaningful economics after direct costs. This provides a stronger foundation for future operating improvement, although the company still needs sufficient scale and cost discipline to convert that margin into profit.
Manageable LeverageLow debt and modest debt relative to equity reduce immediate balance-sheet pressure and preserve financial flexibility compared with the stress seen in 2022–2023. This gives Avicanna more capacity to manage operations while pursuing improvement, despite continuing losses.
Historical Revenue ExpansionMaterial revenue expansion from 2021 through 2024 demonstrates that Avicanna has previously increased its commercial scale. That established base can support operating leverage if growth resumes, though the recent flattening means this remains a historical strength rather than current momentum.
Bears Say
Persistent Cash BurnNegative operating and free cash flow across every reported period means the business has not yet funded itself through operations. Continued cash burn can constrain investment and increase reliance on external financing, making sustained cash break-even a central requirement for stability.
Ongoing UnprofitabilityAvicanna’s negative EBIT, EBITDA, and net income show that its roughly 50%+ gross margin is not yet covering operating costs. Persistent losses weaken internal capital generation and indicate that further scale, expense control, or both are needed before earnings become durable.
Stalling Revenue GrowthFlattening revenue followed by slightly negative TTM growth weakens the near-term path to operating leverage. Without renewed demand or commercial expansion, the company may struggle to spread fixed costs across a larger base, delaying progress toward profitability and cash-flow break-even.
Avicanna News
0NN FAQ
What was Avicanna’s price range in the past 12 months?
Avicanna lowest stock price was €0.06 and its highest was €0.19 in the past 12 months.
What is Avicanna’s market cap?
Avicanna’s market cap is €9.21M.
When is Avicanna’s upcoming earnings report date?
Avicanna’s upcoming earnings report date is Nov 12, 2026 which is in 57 days.
How were Avicanna’s earnings last quarter?
Avicanna released its earnings results on Aug 14, 2026. The company reported -€0.005 earnings per share for the quarter.
Is Avicanna overvalued?
According to Wall Street analysts Avicanna’s price is currently Overvalued.
Does Avicanna pay dividends?
Avicanna does not currently pay dividends.
What is Avicanna’s EPS estimate?
Avicanna’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avicanna have?
Avicanna has 134,383,850 shares outstanding.
What happened to Avicanna’s price movement after its last earnings report?
Avicanna reported an EPS of -€0.005 in its last earnings report. Following the earnings report the stock price went up 3.896%.
Which hedge fund is a major shareholder of Avicanna?
Currently, no hedge funds are holding shares in DE:0NN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avicanna
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses R&D and clinical trials, often undertaken in collaboration with Canadian academic and medical institutions. This effort has yielded around twenty commercialized products spanning four primary market categories. These offerings include medical and wellness items under the RHO Phyto brand, featuring cannabinoids such as CBD, CBG, and THC; CBD-infused topical and derma-cosmetic products marketed under the Pura H&W and Pura Earth labels; and bulk cannabis and hemp-derived raw materials like dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, and isolates, provided through the Aureus brand. Additionally, Avicanna is advancing a pharmaceutical pipeline focused on treatments for conditions including epidermolysis bullosa, dermatological ailments, chronic pain, and various neurological disorders. A notable research partnership with Dr. Christine Allen's Research Group is dedicated to developing a cannabinoid-based therapy for lung inflammation linked to COVID-19.
Technical Analysis
Charlotte's Web Holdings
―
MediPharm Labs
―
PharmaCielo
―
Cardiol Therapeutics
―
InnoCan Pharma
―